Printer Friendly

Global Tinea Pedis Treatment Market to Reach USD 1.7bn by End of 2027, Future Market Insights Forecasts.

M2 PHARMA-November 28, 2017-Global Tinea Pedis Treatment Market to Reach USD 1.7bn by End of 2027, Future Market Insights Forecasts

(C)2017 M2 COMMUNICATIONS

- The global tinea pedis treatment market is estimated to reach a valuation of more than USD 1.7bn by 2027 end from an estimated market value of around USD 1,080m in 2017, growing at a moderate CAGR of 4.8% throughout the period of forecast, according to a new report from US-based Future Market Insights.

The market is assessed across the key regions of North America, Asia Pacific excluding Japan (APEJ), Japan, Latin America, Western Europe, Eastern Europe and the Middle East and Africa and future projections of the global tinea pedis treatment market have been slated for a period of ten years.

As per this analytical research study, the global tinea pedis treatment market is estimated to reach a valuation of more than USD 1.7bn by 2027 end from an estimated market value of around USD 1,080m in 2017, growing at a moderate CAGR of 4.8% throughout the period of forecast.

The global market for tinea pedis treatment is segmented by disease type, by route of administration, by distribution channel, by drug class and by region.

By drug class, the antifungals segment is the largest segment in terms of revenue. This segment has been dominating the global market since 2012 and is likely to continue leading the global market in the coming years.

The steroids and anti-infective combinations segment is projected to grow at the fastest rate to reflect a CAGR of 5.5% during the period of assessment.

By route of administration, the oral segment is expected to witness a comparatively higher growth rate during the forecast period owing to increasing adoption of oral therapies in treating fungal infections. However, the topical segment is higher in valuation and is estimated to reach USD 1,356.6m by the end of the assessment year.

By distribution channel, drug stores is a lucrative segment and is the second largest in terms of value and growth rate.

The hospital pharmacy segment is the largest segment, reflecting a valuation of around USD 402m in 2017 and is likely to lead the global market.

By disease type, the interdigital tinea pedis segment offers high growth opportunities in the tinea pedis treatment market and is expected to grow at a 4.5% CAGR during the said period.

By region, North America is the largest and reflects a high market attractiveness index.

APEJ is the second largest regional market for tinea pedis treatment in terms of valuation and is the fastest growing region with a high CAGR of 6.1% recorded during the period of forecast.

Rise in fungal infections, higher investments in emerging economies, increasing awareness and higher research funding, growing emphasis on enhancing distribution channels, growing preference by podiatrists and dermatologists, increasing public-private partnerships to facilitate new developments for effective treatment of tinea pedis, advancements in personalised medicines and increasing government support are boosting the growth of the global tinea pedis treatment market.

However, the growth of the market is hampered by factors such as high drug costs, lack of diagnostic tools for treatment, fluctuating prices and growing alternatives for tinea pedis treatment.

Future Market Insights is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature.

Key players in this market include Perrigo company, Taro Pharmaceuticals USA., Inc., Teva Pharmaceuticals, Inc., Glenmark Pharmaceuticals Inc., USA, Breckenridge Pharmaceutical, Inc., NorthStar Rx LLC, Aurobindo Pharma Ltd., Camber Pharmaceuticals, Inc., AvKare, Inc., Novartis AG, Sebela Pharmaceuticals Inc., Bayer AG, Blueberry Therapeutics Ltd., GlaxoSmithKline Plc., Exeltis USA, Valeant Pharmaceuticals, Inc., CorePharma, LLC, McNeil Consumer Healthcare, Aqua Pharmaceuticals LLC and Mylan N.V.

((Comments on this story may be sent to info@m2.com))
COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 28, 2017
Words:639
Previous Article:Scarlet fever at 50-year high.
Next Article:BioMarin divests second USD125m priority review voucher.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters